You are in: eMedicine Specialties > Emergency Medicine > DERMATOLOGY Molluscum ContagiosumArticle Last Updated: Apr 10, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Peter P Taillac, MD, Associate Clinical Professor of Surgery, Division of Emergency Medicine, University of Utah Health Sciences Center Peter P Taillac is a member of the following medical societies: American College of Emergency Physicians, National Association of EMS Physicians, and Society for Academic Emergency Medicine Editors: Eric Kardon, MD, FACEP, Associate Staff, Division of Emergency Medicine, Athens Regional Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Mark W Fourre, MD, Program Director, Department of Emergency Medicine, Maine Medical Center; Associate Clinical Professor, Department of Surgery, University of Vermont School of Medicine; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Pamela L Dyne, MD, Associate Professor, Program Director, Department of Medicine, Division of Emergency Medicine, University of California at Los Angeles School of Medicine Author and Editor Disclosure Synonyms and related keywords: molluscum verrucosum, Poxviridae, molluscum bodies, benign viral disease of skin, flesh colored papules with central umbilication, white curdlike core, poxvirus, lesions with waxy appearance and central umbilication INTRODUCTIONBackgroundMolluscum contagiosum is a benign viral disease of the skin that is caused by a member of the poxvirus group, molluscum contagiosum virus (MCV). The virus is one of the largest that causes human disease, measuring 240-320 nm in diameter. Bateman first described the disease in 1817. The term molluscum was used to describe the pedunculated appearance, and the term contagiosum was used to connote that the disease is transmissible. Interestingly, the idea of an infectious etiology arose after successful transmission occurred in humans who were inoculated with the materials contained within the lesions. Goodpasture first noted the microscopic similarities that exist between molluscum contagiosum and vaccinia (ie, smallpox). PathophysiologyThis virus is known to infect only the epidermis. The initial infection seems to occur in the basal layer, and it may be accompanied by a latent period of as long as 6 months. The incubation period is usually shorter (ie, 2-7 wk). This is suggested by the fact that while viral particles are noted in the basal layer, viral DNA replication and the formation of new viral particles do not occur until the spindle and granular layers of the epidermis are involved. Occasionally, the lesions can progress beyond the local cellular proliferation, and they can become inflamed with the attendant edema, increased vascularity, and infiltration by neutrophils, lymphocytes, and monocytes. Usually, this only occurs if there is a secondary bacterial infection or if rupture into the dermis occurs. Cell-mediated immunity is thought to be important in modulating and controlling the infection because children and HIV-infected patients are noted to have more widespread and persistent lesions. The incidence and severity of molluscum in HIV-positive and AIDS patients appears to be inversely related to the CD4 count. More severe cases also have been noted in patients who are receiving prednisone and methotrexate. The virus infrequently induces antibody formation; therefore, it is not strongly immunogenic, and reinfection is common. FrequencyUnited StatesMolluscum contagiosum is a common infection throughout the United States. It accounts for approximately 1% of all diagnoses of skin disorders. The exact incidence in the United States is unknown. Higher incidence in children with eczema as well as in immunocompromised individuals has been documented. The infection is transmitted by close physical contact, fomites, and autoinoculation (whereby the patient manually spreads the infection from one location to another, by touching or scratching). Crowded living conditions, use of public pools, and sharing of clothes and towels by infected persons have all been implicated in the spread of the virus. InternationalMolluscum contagiosum has an incidence of up to 4.5% in some population groups. During a regional outbreak in East Africa, it was estimated that 17% of a village's general population and up to 52% of children older than 2 years developed lesions. Poverty, overcrowding, and poor hygiene play key roles in the propagation of this disease. There appears to be a greater incidence of molluscum in tropical areas, although fairly high incidences have been documented in northern European countries as well. An Australian study found anti-MCV antibodies in 39% of adults older than 50 years, demonstrating exposure to be very common. Mortality/MorbidityMolluscum contagiosum is a benign process; therefore, morbidity and mortality are limited.
Race
SexStudies do not demonstrate any definite difference in incidence between the sexes. AgeInfection with molluscum contagiosum occurs in all age groups, and prevalence seems to be increasing.
CLINICALHistory
Physical
Causes
DIFFERENTIALSDermatitis, Atopic Granuloma, Annulare and Pyogenic Herpes Simplex Herpes Zoster Warts, Genital Warts, Plantar
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Cimetidine (Tagamet) |
|---|---|
| Description | H2 antagonist useful in treating pruritus, urticaria, and contact dermatitis. Mechanisms of action in the treatment of molluscum contagiosum are poorly understood. |
| Adult Dose | 300 mg PO qid; however, dosage can vary |
| Pediatric Dose | 30-40 mg/kg/d PO divided q4h |
| Contraindications | Documented hypersensitivity |
| Interactions | Can increase blood levels of theophylline, warfarin, tricyclic antidepressants, triamterene, phenytoin, quinidine, propranolol, metronidazole, procainamide, and lidocaine |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Elderly persons may experience confusional states; may cause impotence and gynecomastia in young males; may increase levels of many drugs; adjust dose or discontinue treatment if changes in renal function occur |
Presumably, antiviral drugs may interfere with ability of molluscum contagiosum virus to replicate.
| Drug Name | Cidofovir (Vistide) |
|---|---|
| Description | Selective inhibitor of viral DNA production in CMV and other herpes viruses. One case report showed improvement in 3 of 3 patients with HIV and extensive co-infection with molluscum contagiosum.2 Improvement was noted with topical or IV formulations. |
| Adult Dose | 5 mg/kg IV over 1 h, once q2wk May be applied topically to lesions, as 3% solution, 5 times/wk for 8 wk |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; coadministration with other nephrotoxic agents; serum creatinine >1.5 mg/dL; a CrCl <55 mL/min; urine protein >100 mg/dL |
| Interactions | Coadministration of aminoglycosides, amphotericin B, IV pentamidine, and foscarnet may increase nephrotoxicity |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Monitor neutrophil counts; renal toxicity is major adverse effect; prehydrate with normal saline IV and coadminister probenecid with each infusion to minimize nephrotoxicity (monitor renal function); monitor serum creatinine and urine protein 48 h prior to treatment (adjust dose accordingly); granulocytopenia may occur; topical use may lead to varioliform scarring |
Cause cornified epithelium to swell, soften, macerate, and then desquamate.
| Drug Name | Cantharidin (Verr-Canth) |
|---|---|
| Description | Causes inflammatory reaction to lesion, causing expulsion of lesion contents. Unlikely to scar. Painful if applied to surrounding, intact skin. 90% successful in clearing of lesion. |
| Adult Dose | 0.7% solution, in flexible collodion; apply every month directly to visible lesions, avoiding surrounding skin; wash off in 2-6 h, or at first sign of blistering |
| Pediatric Dose | Administer as in adults; pretreatment with acetaminophen or ibuprofen may minimize discomfort experienced with blistering |
| Contraindications | Documented hypersensitivity; diabetes; impaired peripheral circulation; use on eyes, mucous membranes, anogenital or intertriginous areas, moles, or birthmarks; lesions caused with other agents or if surrounding tissue is swollen or irritated; avoid facial application |
| Interactions | None reported |
| Pregnancy | A - Fetal risk not revealed in controlled studies in humans |
| Precautions | Strong vesicant to be used sparingly; not for use in the anogenital area; not for application to eyes and mucosal tissue; avoid use in intertriginous sites due to problems with spreading and body occlusion, which often lead to more intense, painful reactions; avoid facial use |
These agents are used to inhibit deregulated cell growth and eliminate viral infected cells.
| Drug Name | Podophyllum resin (Pod-Ben-25, Podocon-25) |
|---|---|
| Description | Isolated from resins that are found in plants (eg, May apple, mandrake). A multicenter, double-blinded, placebo-controlled study involving 150 patients demonstrated cure rates of 16%, 52%, and 92% in control, 0.3% and 0.5% creams, respectively.3 Treatment was bid for 3 d and extended to 4 wk if not resolved within the initial 3 d. |
| Adult Dose | Apply for 30-40 min to determine patient's sensitivity, and subsequent doses are applied sparingly according to clinical effect (ie, 1-4 h); following elapsed time, material should be removed with an alcohol swab or soap and water |
| Pediatric Dose | Apply as in adults |
| Contraindications | Documented hypersensitivity; diabetes; impaired peripheral circulation; avoid use on mucous membranes, eyes, bleeding warts, moles, birthmarks, or unusual warts with hair |
| Interactions | None reported |
| Pregnancy | X - Contraindicated; benefit does not outweigh risk |
| Precautions | Do not use on lesions that appear to be secondarily infected; do not use large amounts of the drug and avoid contact with the cornea; the 25% solution should not be applied near the mucous membranes |
| Drug Name | Salicylic acid and liquid nitrogen |
|---|---|
| Description | These medications are used to destroy or remove lesions. They are applied topically and often are applied multiple times with intervening debridement of the lesions. |
| Adult Dose | Apply sparingly to affected area |
| Pediatric Dose | Apply as in adults |
| Contraindications | Documented hypersensitivity; diabetes; impaired peripheral circulation; do not use on eyes, mucous membranes, ano-genital or intertriginous areas, moles, birthmarks, or unusual warts with hair; do not use on lesions with other agents or if surrounding tissue is swollen or irritated |
| Interactions | None reported |
| Pregnancy | A - Fetal risk not revealed in controlled studies in humans |
| Precautions | Avoid contact with eyes and mucous membranes; if contact with eyes or mucous membranes occurs, immediately flush with water for 15 min; avoid inhaling the vapors |
Vitamin A derivatives have many roles. They encourage cellular differentiation, are antiproliferative, and serve as immunomodulators.
| Drug Name | Tretinoin (Retin-A, Renova) |
|---|---|
| Description | Inhibits microcomedo formation and eliminates lesions. Makes keratinocytes in sebaceous follicles less adherent and easier to remove. Available as 0.025%, 0.05%, and 0.1% creams. Available also as 0.01% and 0.025% gels. Begin with lowest tretinoin formulation and increase as tolerated. |
| Adult Dose | Tretinoin 0.1% cream is applied to lesions qod; advance to bid as tolerated for 4-6 wk; cease application if erythema develops Tretinoin 0.05% cream also used with success |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; pregnancy |
| Interactions | Other skin irritants (ie, astringents, benzoyl peroxide, salicylic acid, resorcinol, topical sulfur, other keratolytics, abrasives, astringents, spices, lime) may exacerbate irritation; coadministration with other drugs causing photosensitivity (eg, tetracycline, sulfonamides) may increase risk of sunburn |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Photosensitivity may occur with excessive sunlight exposure; burning, stinging, peeling, pruritus, or erythema has been reported at site of application; caution with eczema (may cause severe irritation); avoid contact with mucous membranes, mouth, and angles of nose |
These agents may have immunomodulatory effects.
| Drug Name | Imiquimod (Aldara) |
|---|---|
| Description | Imiquimod 5% cream has been used topically to treat MCV. Induces secretion of interferon alpha and other cytokines; mechanism of action are unknown. It is a potent immunomodulatory agent. May be more effective in women than in men. |
| Adult Dose | 5% cream: Apply 3 times qwk hs; leave on skin for 6-10 h |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Genital use: Not recommended for treatment of rectal, cervical, intravaginal, urethral, and intra-anal human papilloma infection; following surgery or drug treatment, do not use topical imiquimod until genital/perianal tissue is healed Actinic keratosis: Avoid exposure to sunlight or artificial tanning; regular use of sunscreen is encouraged; avoid contact with lips, eyes, or nostrils; common adverse effects include erythema, edema, vesicles, erosion or ulceration, weeping, exudate, flaking, scaling, dryness, and scabbing or crusting Basal cell carcinoma: Medical follow-up is essential to assure cancer has responded adequately to treatment; may cause redness, swelling, and sore development at application site; may cause itching or burning |
The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Stephen Bretz, MD, to the development and writing of this article.
| Media file 1: Typical molluscum lesions on buttocks. Photo courtesy of F. Fehl III, MD. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Molluscum lesions on face and neck. Photo courtesy of F. Fehl III, MD. | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Apr 10, 2008